Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNP 1-28
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Parenteral
01
Overview
LNP 1-28 is a preclinical lipid nanoparticle formulation developed by University Health Network to deliver small interfering RNA into acute myeloid leukemia cells and primary acute myeloid leukemia samples. The formulation supports intracellular RNA interference by enabling siRNA delivery and gene silencing; in reported laboratory experiments, LNP1-28 produced luciferase knockdown in AML cell lines and delivered siRNA directed against CD45. Its therapeutic target is payload-dependent rather than intrinsically defined by the nanoparticle formulation. ([aacrjournals.org](https://aacrjournals.org/cancerres/article/85/8_Supplement_1/1792/756713/Abstract-1792-A-novel-lipid-nanoparticle))
02
Targets
CFTR (Cystic fibrosis transmembrane conductance regulator)
Beyond the preview
Go deeper on LNP 1-28.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNP 1-28.